Citius Oncology Launches LYMPHIR Amidst Going Concern Doubts

Ticker: CTOR · Form: 10-K · Filed: Dec 23, 2025 · CIK: 1851484

Sentiment: bearish

Topics: Biotechnology, Oncology, Rare Disease, FDA Approval, Commercialization, Going Concern, Controlled Company

Related Tickers: CTXR

TL;DR

**CTOR's LYMPHIR launch is a high-stakes gamble; the 'going concern' warning and heavy reliance on Citius Pharma make this a speculative play for aggressive traders.**

AI Summary

Citius Oncology, Inc. (CTOR) is a biopharmaceutical company focused on targeted oncology therapies, with its lead product LYMPHIR™ (denileukin diftitox) approved by the U.S. FDA in August 2024 and launched in December 2025 for persistent or recurrent CTCL. The company projects an underserved market for LYMPHIR exceeding $400 million. CTOR became a standalone publicly-traded company in August 2024 through a reverse merger with TenX Keane Acquisition, with Citius Pharmaceuticals, Inc. (Citius Pharma) initially owning 92% and subsequently 77.9% as of December 17, 2025. Citius Pharma continues to fund Citius Oncology and provides management and scientific services under an A&R Shared Services Agreement. The company faces substantial doubt about its ability to continue as a going concern, requires significant additional funding, and has a history of net losses, expecting further losses in the foreseeable future. The Phase 3 trial (E7777-G000-302) for LYMPHIR demonstrated an Objective Response Rate (ORR) of 25 out of 69 subjects in the primary efficacy analysis set for Stage I-III CTCL patients.

Why It Matters

Citius Oncology's launch of LYMPHIR for CTCL could offer a new treatment option for patients in an underserved market estimated to exceed $400 million, potentially impacting patient outcomes and physician choices. For investors, the company's 'going concern' warning and reliance on Citius Pharma for funding and services present significant risks, despite the product approval. The competitive landscape in oncology, particularly for rare lymphomas, means LYMPHIR's market acceptance will be crucial. Employees face uncertainty given the financial instability, while the broader market watches how a newly public, controlled company navigates commercialization with substantial financial hurdles.

Risk Assessment

Risk Level: high — The filing explicitly states, "Our independent registered public accounting firm's report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern." This, coupled with the need for "substantial additional funds" and a history of "net losses" with expectations of future losses, indicates a very high financial risk. The aggregate market value of non-affiliate common equity was only $5,097,850 as of March 31, 2025.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the company's ability to secure additional funding and achieve market acceptance for LYMPHIR. Given the 'going concern' warning and significant reliance on Citius Pharma, a wait-and-see approach to observe commercialization progress and financial stability improvements is advisable before considering an investment.

Key Numbers

Key Players & Entities

FAQ

What is Citius Oncology's lead product and its target market?

Citius Oncology's lead product is LYMPHIR™ (denileukin diftitox), an engineered IL-2 diphtheria toxin fusion protein. It is approved for the treatment of patients with persistent or recurrent Cutaneous T-cell Lymphoma (CTCL), a rare form of non-Hodgkin lymphoma. The company estimates this market to exceed $400 million.

When was LYMPHIR approved by the FDA and when did Citius Oncology launch it?

LYMPHIR was approved by the U.S. Food and Drug Administration (FDA) in August 2024. Citius Oncology subsequently launched the product in December 2025.

What is the financial outlook for Citius Oncology, Inc. based on the 10-K filing?

The 10-K filing indicates a challenging financial outlook for Citius Oncology, Inc. The company's independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about its ability to continue as a going concern. Citius Oncology also requires substantial additional funding and has a history of net losses, expecting to incur further losses for the foreseeable future.

What is Citius Pharmaceuticals, Inc.'s relationship with Citius Oncology, Inc.?

Citius Pharmaceuticals, Inc. (Citius Pharma) is the majority owner of Citius Oncology, Inc., holding approximately 77.9% of its common stock as of December 17, 2025. Citius Pharma also funds Citius Oncology and provides management and scientific services under an amended and restated shared services agreement.

What were the key efficacy results from the Phase 3 trial for LYMPHIR?

The Phase 3 trial (E7777-G000-302) for LYMPHIR showed an Objective Response Rate (ORR) of 25 responders out of 69 subjects in the Primary Efficacy Analysis Set. This set included patients with CTCL disease Stages I to III who received 9 g/kg/day of LYMPHIR.

What are the primary risks highlighted in Citius Oncology's 10-K?

Key risks include substantial doubt about the company's ability to continue as a going concern, the need for significant additional funding, a history of net losses, and the unproven business strategy for LYMPHIR's commercialization. There are also risks related to milestone payments, potential breaches of license agreements, and reliance on third-party manufacturers.

How does Citius Oncology plan to commercialize LYMPHIR in the U.S. and internationally?

Citius Oncology intends to commercialize LYMPHIR independently in the U.S. by establishing a small, targeted oncology sales force focused on key geographies and major cancer centers. For markets outside of the U.S., the company plans to partner with other entities to market its products.

What was the aggregate market value of Citius Oncology's common equity held by non-affiliates?

As of March 31, 2025, the last business day of the registrant's most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates was $5,097,850.

What is the significance of Citius Oncology being a 'controlled company' under Nasdaq standards?

As a controlled company under Nasdaq standards, Citius Oncology may rely on exemptions from certain governance requirements. This could limit the protections afforded to its stockholders compared to those of other companies that are not controlled, potentially impacting corporate governance practices.

What is the mechanism of action for LYMPHIR?

LYMPHIR is a recombinant DNA-derived fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells expressing the IL-2 receptor. After cellular uptake, the DT fragment inhibits protein synthesis, leading to cell death. This mechanism supports killing tumors by delivering diphtheria toxin directly to tumor cells and depleting immunosuppressive regulatory T lymphocytes (Tregs) to enhance antitumor activity.

Risk Factors

Industry Context

Citius Oncology operates in the biopharmaceutical sector, specifically focusing on targeted oncology therapies. The market for rare cancer treatments like CTCL is often underserved, presenting opportunities for companies with innovative therapies. However, the industry is highly competitive, with significant R&D costs, long development cycles, and stringent regulatory hurdles.

Regulatory Implications

The FDA approval of LYMPHIR in August 2024 is a critical de-risking event. However, ongoing compliance with post-market surveillance requirements and potential future regulatory scrutiny remain important considerations. The company's strategy of using previously approved drug components may reduce some development risks but does not eliminate regulatory challenges.

What Investors Should Do

  1. Monitor LYMPHIR's commercial launch performance closely.
  2. Assess the company's ability to secure additional funding.
  3. Evaluate the competitive landscape for CTCL treatments.

Key Dates

Glossary

CTCL
Cutaneous T-cell Lymphoma, a rare type of non-Hodgkin lymphoma that affects the skin. (This is the primary indication for the company's lead drug, LYMPHIR.)
LYMPHIR™ (denileukin diftitox)
An engineered IL-2 diphtheria toxin fusion protein developed by Citius Oncology for treating CTCL. (This is the company's lead product, which has received FDA approval and is central to its business strategy.)
Objective Response Rate (ORR)
A measure of how many patients in a clinical trial respond to a treatment, typically defined as a complete or partial response. (This metric was used in the Phase 3 trial for LYMPHIR, with an ORR of 25 out of 69 subjects, indicating treatment efficacy.)
Going Concern
An accounting term referring to the assumption that a business will continue to operate for the foreseeable future without the threat of liquidation. (The company faces substantial doubt about its ability to continue as a going concern, highlighting significant financial risks.)
Reverse Merger
A transaction where a private company becomes public by merging with an existing public shell company. (Citius Oncology became a public company through a reverse merger with TenX Keane Acquisition.)

Year-Over-Year Comparison

This 10-K filing reflects significant advancements since the previous reporting period, most notably the FDA approval of LYMPHIR in August 2024 and its planned launch in December 2025. The company has transitioned from a development-stage entity to a commercial-stage one, albeit with substantial financial challenges. New risks related to commercialization and market adoption have emerged, while the fundamental risk of needing significant additional funding persists.

Filing Stats: 4,542 words · 18 min read · ~15 pages · Grade level 12.7 · Accepted 2025-12-23 16:20:48

Key Financial Figures

Filing Documents

Business

Business 1 Item 1A.

Risk Factors

Risk Factors 18 Item 1B. Unresolved Staff Comments 47 Item 1C. Cybersecurity 47 Item 2.

Properties

Properties 48 Item 3.

Legal Proceedings

Legal Proceedings 48 Item 4. Mine Safety Disclosures 48 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 49 Item 6. [Reserved] 49 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 50 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 56 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 56 Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 56 Item 9A.

Controls and Procedures

Controls and Procedures 56 Item 9B. Other Information 57 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 57 PART III Item 10. Directors, Executive Officers and Corporate Governance 58 Item 11.

Executive Compensation

Executive Compensation 64 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 69 Item 13. Certain Relationships and Related Transactions, and Director Independence 70 Item 14. Principal Accountant Fees and Services 72 PART IV Item 15. Exhibits and Financial Statement Schedules 73 Item 16. Form 10-K Summary 74

Signatures

Signatures 75 i NOTES In this annual report on Form 10-K, and unless the context otherwise requires, the "Company," "Citius Oncology" "we," "us" and "our" refer to Citius Oncology, Inc. and its wholly-owned subsidiary Citius Oncology Sub Inc., "Citius Oncology Sub", taken as a whole. LYMPHIR TM (denileukin diftitox) is our registered trademark. All other trade names, trademarks and service marks appearing in this annual report are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms, when first mentioned in this report, appear with the trade name, trademark or service mark notice and then throughout the remainder of this report without trade name, trademark or service mark notices for convenience only and should not be construed as being used in a descriptive or generic sense.

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains "forward-looking plans, strategies, predictions, or any other statements relating to our future activities or other future events or conditions. These These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking Factors," and Item 7 - "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this report and in other documents which we file with the Securities and Exchange Commission ("SEC"). In addition, such our independent registered public accounting firm's report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern; our need for substantial additional funds and its ability to raise those funds; our ongoing evaluation of strategic alternatives; our ability to successfully commercialize LYMPHIR, including covering the costs of licensing payments, product manufacturing and other third-party goods and services; the ability of LYMPHIR or any of our future product candidates to impact the quality of life of our target patient populations; the estimated markets for LYMPHIR or any of our future product candidates and the acceptance thereof by any market; our ability to recognize the anticipated benefits of

Business

Item 1. Business Business Overview The Company, headquartered in Cranford, New Jersey, is a biopharmaceutical company focused on developing and commercializing innovative targeted oncology therapies. The Company's strategy centers on achieving a market leading position by advancing innovative therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The Company's lead product is LYMPHIR TM , an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR was approved by the U.S. Food and Drug Administration (the "FDA") in August 2024 and was launched in December 2025. The Company believes there is an attractive and growing market for LYMPHIR, estimated to exceed $400 million, that is underserved by existing treatments. See below for more detailed information on LYMPHIR. The Company intends to commercialize our products independently in the U.S., and partner to market products outside of the U.S. The Company has established a small, targeted oncology sales force, initially for LYMPHIR, focused on key geographies and stakeholders, primarily major cancer centers. This commercialization strategy is anticipated to result in a combination of direct sales revenue, and royalty income, as well as incremental operating expenses and greater working capital requirements. Citius Oncology and the Merger On August 23, 2021, Citius Pharma formed Citius Acquisition Corp. ("SpinCo") as a wholly-owned subsidiary in conjunction with the acquisition of LYMPHIR, SpinCo began operations in April 2022, when Citius Pharma transferred the assets related to LYMPHIR to SpinCo, including the related license agreement with Eisai Co., Lt

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing